Refine by
Pain Clinic Articles & Analysis
37 news found
Cebranopadol is a novel, dual nociceptin/orphanin FQ peptide (NOP) receptor and μ-opioid peptide (MOP) receptor agonist in development for the treatment of moderate to severe pain. Multiple clinical studies have demonstrated that cebranopadol is efficacious in different types of pain. ...
Iterative Health, formerly known as Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, has announced a rebrand to reflect the company’s success in utilizing artificial intelligence (AI) to strengthen clinical research and augment clinical decision making within gastroenterology. ...
Major investment to support Oncomfort’s roadmap Founded in 2017, Oncomfort is a Belgian scale-up specialized in Digital Sedation, a completely new method for relieving patients’ pain and anxiety through treatment with clinically proven sessions of therapeutic Virtual Reality. Since the launch of the Sedakit™ for Digital Sedation in Benelux and ...
” The SP301 study determined that a self-administered treatment protocol using the Relivion home based technology can provide a clinically significant safe and effective reduction of migraine-related pain. The device was shown to be significantly effective across all of the study’s pre-defined end points and demonstrated clinically ...
We believe, before long, we will get the attention of large pharmaceutical companies looking to collaborate with us as we move towards the clinic and establish our technology as a leading edge non-opioid treatment for inflammation and neuropathic pain,” said Dean Petkanas, CEO of Neuropathix. ...
(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available for purchase through many of the more than 130 National Spine and Pain Centers (NSPC) affiliated locations across the United States for patients suffering from pain associated with ...
We believe that a successful safety study under a Phase I clinical trial can begin to open other doors that involve inflammatory processes in the field of treating neuropathic pain. ...
About KLS-13019 KLS-13019 is Neuropathix patented lead clinical compound for the potential treatment of a range of inflammatory, neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 is a monotherapeutic non-opioid cannabinoid derivative that has been shown to prevent and reverse neuropathic ...
“The groundbreaking technology behind the Evoke System’s ability to intelligently measure spinal cord activation has had many of us excited for a long time,” said Nagy Mekhail, MD, PhD, Professor at the Cleveland Clinic Lerner College of Medicine, Director of Evidence-Based Pain Medicine Research and Education in the Department of ...
The Company executed the first double-blind pivotal randomized controlled trial (RCT) in the history of spinal cord stimulation (SCS) that showed nearly 9 out 10 patients experience long-term pain relief and clinically meaningful improvements in quality of life, performing activities of daily living, sleep, mood and opioid reduction with zero explants due to loss ...
“Modulating stimulation pulse width has the potential to selectively recruit particular nerve fibers that could benefit patients with difficult to address pain patterns. With the introduction of a pulse width expanded to 2,000 microseconds, I now have one more tool to help address the short- and long-term pain relief needs of individual patients suffering ...
Oncomfort, the leader in Digital SedationTM for relieving patients’ pain and anxiety without medication, is pleased to announce the appointment of Karl Schweitzer as non-executive Director and Chairman of the Board. With this appointment, Oncomfort brings on board the experienced leadership to guide the organisation in its global expansion and significant knowledge for the ...
(NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today responded to Medtronic's announcement of FDA approval for painful diabetic neuropathy (PDN). ...
About KLS-13019 KLS-13019 is Neuropathix patented lead clinical target for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 is a monotherapeutic non-opioid cannabinoid derivative that has been shown to prevent and reverse neuropathic ...
SENZA-NSRBP Randomized Controlled Trial Results Show Profound Improvements in Non-Surgical Refractory Back Pain Patients Receiving 10 kHz Therapy Relative to Conventional Medical Management at 12-Months Follow-Up. ...
Department of Defense, the company will conduct a phase 2 clinical trial for a plague vaccine adjuvanted with CpG 1018 which is anticipated to initiate in the second half of 2022. Further advancement of product candidates with CpG 1018 adjuvant through pre-clinical and clinical collaborations and additional discovery efforts, including ongoing ...
Significant findings of Evoke ECAP-controlled closed-loop in the EVOKE Study at 24 months include: Superiority in treatment of overall back and leg pain and long-term pain reduction Highest long-term responder (≥50% relief) and high responder (≥80% relief) rates, 84% and 50%, respectively Highest reported improvements in overall quality of life, ...
Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced 24-month results from a Level 1, prospective, randomized, multi-center trial (INTRACEPT) that further validate the safety, effectiveness, and durability of the Intracept® Procedure for patients with vertebrogenic CLBP. ...
About KLS-13019 KLS-13019 is Neuropathix patented lead clinical target for the potential treatment of a range of neurotoxic, neurodegenerative and neuropathic pain disorders, beginning with CIPN. KLS-13019 is a monotherapeutic non-opioid cannabinoid derivative that has been shown to prevent and reverse neuropathic pain in ...
In a highly anticipated document published online yesterday in Circulation and the Journal of the American College of Cardiology, the Joint Committee on Clinical Practice Guidelines for the American College of Cardiology & American Heart Association released new clinical practice guidelines for managing patients with Acute and Stable chest ...
ByElucid